Kenya has recorded its second death from Ebola, and on the same day the Democratic Republic of Congo began vaccinating the first participants in a landmark trial designed to answer the most pressing scientific question of the outbreak: can any existing vaccine stop the Bundibugyo strain? The two developments, announced on Friday, capture the outbreak's dual character — containment holding in one country, and a race for evidence unfolding in another, where the epidemic has already infected nearly 10,000 people.

Kenya's health ministry said the latest victim was a 65-year-old woman who was a direct contact and close family member of the country's first case, and who was already in quarantine when she developed symptoms on October 13, according to Reuters. Her death brings Kenya's toll to two among nine confirmed cases; the remaining seven patients are receiving care in two isolation facilities.

A single cluster, and a system that caught the case early

The details of the second death matter as much as the headline number. The woman was identified through contact tracing, isolated before she became symptomatic, and monitored throughout — the textbook sequence that public health officials hope to see. Kenya's ministry stressed that all cases belong to "one cluster, with no evidence of community spread," a formulation repeated in its statements since the outbreak reached the country.

Kenya had never recorded an Ebola case until October 6, when a Kenyan man who had been living in the Democratic Republic of Congo died after returning home. Since then, authorities have traced 135 contacts, all placed in quarantine, with nine cases confirmed. The speed of that tracing operation is the reason officials can still describe the situation as contained — but the second death is a reminder that quarantine limits transmission; it does not guarantee survival for those already infected.

The international response has already tightened around Kenya. The United States warned its citizens against travel to the country after an eighth case was reported, raising its travel advisory level over health risks. That kind of advisory carries real economic weight for a country where tourism is a major employer, and it raises the stakes of every new case announcement.

The outbreak's widening map

The Congolese outbreak, declared in May, is now the country's 17th — and its worst ever, with more than 9,700 cases and over 4,600 deaths. What makes it historically distinct is its geography: cases have now been reported in four African countries across eastern, central and western Africa, the widest spread of any Ebola outbreak on the continent to date.

Nigeria became the fourth country to report a case this week, and its investigation has troubled epidemiologists: officials are still working out how and where the patient, who had not travelled to the Democratic Republic of Congo, contracted the virus. Uganda, which recorded 20 infections and two deaths earlier in the outbreak, was declared Ebola-free in August. The pattern — a giant epicentre, satellite clusters, and at least one case with an unexplained chain of infection — is precisely why the World Health Organization triggered a public health emergency of international concern, its second-highest alert level.

Related reading: DR Congo Ebola outbreak passes 4,000 deaths · Kenya Ebola travel advisories and the WHO response · Nigeria confirms its first Ebola case

'Tumaini': hope, in trial form

In Bunia, the capital of the DRC's northeastern Ituri province and the epicentre of the outbreak, the first participants in the new vaccine trial were vaccinated on Friday. The trial is called Tumaini — "hope" in Swahili — and it is coordinated by the Coalition for Epidemic Preparedness Innovations (CEPI), with support from the WHO and the Congolese health ministry, according to Al Jazeera.

WHO Director-General Tedros Adhanom Ghebreyesus announced the start on social media, writing: "Science gives us hope. Today, in Bunia, the first participants were vaccinated in a new Ebola vaccine trial called TUMAINI. There is currently no approved vaccine against the Bundibugyo virus causing the outbreak."

The scientific gap the trial addresses is stark. Ervebo, the vaccine being tested first, is licensed against the more common Zaire strain of Ebola — not the Bundibugyo strain driving this epidemic. Earlier this year the DRC received 70,000 Ervebo doses from the global stockpile, but their effectiveness against Bundibugyo is unproven; hundreds of frontline workers have already received the jab under research protocols and compassionate-use arrangements. Tumaini is designed as a single trial framework that can test multiple candidates in sequence: Ervebo first, followed by two Bundibugyo-specific vaccines — one adenoviral-vector candidate from the University of Oxford and one mRNA candidate from Moderna — as they advance through earlier-stage trials.

Anthony Scott, chair of the WHO's Strategic Advisory Group of Experts on Immunisation, said the trial would generate "urgently-needed data on the efficacy of Ervebo against Bundibugyo" and help shape the policy decisions governments need. Kate O'Brien, director of the WHO's immunisation department, said a technical advisory group would review evidence from the smaller trials of the Oxford and Moderna candidates.

Why a trial in the middle of an outbreak matters

Running a full-scale efficacy trial during an active epidemic is difficult and, to some, ethically fraught — participants are recruited in communities where the virus is killing neighbours. But the alternative is worse: deploying vaccines for years on the basis of hope rather than evidence, and discovering too late that they do not work against the strain actually circulating. The Bundibugyo strain has caused outbreaks since May with no licensed vaccine and no approved specific treatment; every previous Bundibugyo response has relied on supportive care, isolation and contact tracing alone.

That is what makes Tumaini more than a research milestone. If Ervebo shows cross-protection, health authorities gain an immediately deployable tool from existing stockpiles. If it does not, the result redirects scarce resources toward the Bundibugyo-specific candidates rather than a false sense of security. Either answer is valuable — but only a trial of this scale can provide it.

What to watch next

Several markers will show whether the outbreak is bending toward control or toward a longer crisis:

  • Kenya's case count. A tenth case outside the known cluster would break the "no community spread" assessment and likely trigger tougher travel measures.
  • Nigeria's source investigation. Finding — or failing to find — how its first patient was infected will shape whether western Africa faces a separate transmission chain.
  • Tumaini's pace. The trial's credibility depends on enrolling enough participants quickly in Ituri, where insecurity and mistrust have complicated past responses.
  • The advisory-group verdict. The WHO technical review of the Oxford and Moderna candidates will decide whether Bundibugyo-specific vaccines join the trial soon, or remain years away.

For now, the picture is one of containment under strain and science racing to catch up. Kenya's second death shows the virus still kills even inside a well-run quarantine system. The first jabs in Bunia show the world finally testing whether it has a vaccine that can stop this strain at all. Both stories will be measured in the same currency over the coming weeks: cases that do not happen.

Frequently Asked Questions

What happened in Kenya on October 23, 2026?

Kenya's health ministry confirmed its second Ebola death: a 65-year-old woman who was a close family member and direct contact of the country's first case. She was in quarantine when she developed symptoms on October 13. Kenya now has nine confirmed cases and two deaths, with seven patients in treatment at two isolation facilities and no evidence of community spread.

What is the Tumaini vaccine trial?

Tumaini — Swahili for "hope" — is a full-scale vaccine trial launched in Bunia, in the DRC's Ituri province, on October 23, 2026. Coordinated by CEPI with WHO and Congolese health ministry support, it will first test whether Ervebo, a vaccine licensed for the Zaire strain, offers cross-protection against the Bundibugyo strain, and may later test Bundibugyo-specific candidates from Oxford and Moderna.

Why is there no approved vaccine for this outbreak's strain?

The current outbreak is caused by the Bundibugyo species of Ebola virus. The only licensed Ebola vaccine, Ervebo, targets the different Zaire species, and its effectiveness against Bundibugyo has never been proven in a full-scale trial. No vaccine or specific treatment has yet been approved for Bundibugyo, which is why the Tumaini trial is considered so important.

How large is the DRC outbreak?

The DRC declared its 17th Ebola outbreak in May 2026. It has since grown into the country's worst-ever outbreak, with more than 9,700 cases and over 4,600 deaths, and has spread to four African countries — the widest geographic spread of any Ebola outbreak on the continent.

Can Ebola spread from people without symptoms?

No. Only people who have developed symptoms can transmit the virus, which is why contact tracing and quarantine of exposed people — as Kenya did with its second victim — are central to stopping transmission. The disease causes fever, vomiting and diarrhoea and, in severe cases, internal and external bleeding.